echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Qilu anti-tumor drug first imitation, injection first over-evaluation, 700 million varieties of the third domestic

    Qilu anti-tumor drug first imitation, injection first over-evaluation, 700 million varieties of the third domestic

    • Last Update: 2021-01-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 5, NMPA's official website announced the latest drug approval information, Qilu Pharmaceuticals won three products in one go: qufluoruricoside tablets domestic first imitation, hydrochloric acid Fashudir injection first evaluation, hydrochloric acid Prakso tablets domestic third.
    meters intranet data show that the current Qilu's Enqutaibin capsule class 3 imitation listing application has also entered the "in the approval" state, is expected to usher in good news in the near future.
    Figure 1: Qilu Pharmaceutical's latest approved product situation Source: NMPA official website quefluoruricoside tablets first imitation is known to be qufluorouriacine tablets are quefluorurialine (FTD) and hydrochloric acid tablets An oral compounding agent consisting of 1:0.5 molar ratio for the treatment of metastatic colorectal cancer, originally developed by Dapeng, Japan, and imported by NMPA in August 2019.
    Figure 2: Qufluorouricoside tablets declared listed enterprises source: MiNet MED2.0 China Drug Review Database Minet data show that the current declaration of quefluorouruclein tablets counterfeit listed enterprises have 2, is the first to declare, but finally by Qilu to take the first imitation.
    the first evaluation of the hydrochloric acid Fasshudir injection of hydrochloric acid Fasshudir injection of the adaptive disorders to improve and prevent subcellulation of cobwebs after cerebrovascular spasms and caused by cerebral ischemia symptoms, in China's urban public hospitals, county-level public hospitals, urban community centers and townships Terminal sales at health hospitals (China's public medical institutions) reached nearly 1 billion in 2015 and growth has declined in recent years, with less than 500 million in 2019, but the product ranks top2 in the list of surrounding vascular dilation drug injections, and the market position remains strong.
    the competitive landscape, Tianjin Red Day Pharmaceuticals led the market with 57.62 percent in the first half of 2020, with Qilu Pharmaceuticals' market share of less than 1 percent.
    Table 1: Declaration of hydrochloric acid Fashudir injection consistency evaluation supplementary application of the enterprise source: Minet MED2.0 China Drug Review Database is currently, in addition to Qilu's first evaluation, the enterprises reporting hydrochloric acid Fashudir injection consistency evaluation supplementary application also have Yangzijiang, Yuandong, Bert, Red Day and other 5, Abao Pharmaceuticals according to the new classification declaration is also under review and approval.
    A third domestic figure 3 of the prakso hydrochloric acid tablets: currently obtained the approval of the hydrochloric acid Prakso tablets of the enterprise source: Minenet one-click retrieval of the signs and symptoms of the hydrochloric acid Prakso tablets for the treatment of idiopathic Parkinson's disease, alone (no L-Doba) or in combination with lon doba.
    2019, prakso hydrochloride tablets topped the list with sales of nearly 700 million in top-of-the-line anti-Parkinson's drug products in China's public medical facilities.
    In the current domestic market Grigg Ingeham occupies more than 90% of the market, Beijing New Pharmaceuticals in 2018 won the first imitation (October 2020 through the consistent evaluation), stone medicine in January 2020 with 4 types of imitations approved and treated as the same, Qilu this time is also approved according to 4 types of imitations, become the third domestic "approved and evaluated" enterprises.
    sources: Milnet database, NMPA official website review data statistics as of January 5, 2021, if there are errors, please point out.
    original title: "Heavy" Qilu approved! Anti-tumor drug first imitation, injection first over-evaluation, 700 million varieties of domestic third
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.